AKERS BIOSCIENCES, INC. NON-QUALIFIED STOCK OPTION AGREEMENT EMPLOYEENon-Qualified Stock Option Agreement • December 6th, 2013 • Akers Biosciences Inc • In vitro & in vivo diagnostic substances
THIS NON-QUALIFIED STOCK OPTION AGREEMENT (the “Agreement”) entered into as of the ____ day of ______, 201__ by and between Akers Biosciences, Inc. (the “Company”) and _____________ (the “Optionee”).
INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • December 6th, 2013 • Akers Biosciences Inc • In vitro & in vivo diagnostic substances • New York
This Incentive Stock Option Agreement (“Agreement”) is made and entered into as of the date set forth below, by and between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), and the employee of the Company named in Section 1(b). (“Optionee”):
AKERS BIOSCIENCES, INC. RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • December 6th, 2013 • Akers Biosciences Inc • In vitro & in vivo diagnostic substances
THIS RESTRICTED STOCK AGREEMENT (the “Agreement”) is made and entered into as of the ____ day of __________, 20__ (the “Effective Date”) by and between Akers Biosciences, Inc., a New Jersey corporation (the “Company”), having an address at 201 Grove Road, Thorofare, New Jersey 08086 and __________________ (“Grantee”), having an address at _________________________________________.
Akers Biosciences, Inc.Akers Biosciences Inc • December 6th, 2013 • In vitro & in vivo diagnostic substances • New Jersey
We refer to that certain Subscription Agreement, dated September 14, 2012, by and between Akers Biosciences, Inc., a corporation incorporated under the laws of the State of New Jersey (the “Company”), and you, Thomas J. Knox (“Knox”), an individual residing at 50 South 16th Street, Suite 4604, Philadelphia, PA, 19102 , to purchase, among other things, 10,000,000 shares of the Company’s Series A Cumulative Convertible Preferred Stock (the “Series A Preferred Stock”). In accordance with the terms of the Series A Preferred Stock, as set forth in the certificate of designation, you have the right to convert the Series A Preferred Stock upon completion of (i) payment to the Company of an aggregate principal amount of an additional $500,000 (the “Purchase Price”); (ii) repayment (the “Note Repayment”) of the aggregate principal amount and all accrued interest due under that certain Promissory Note (as defined in the Subscription Agreement) and (iii) an increase in the Company’s authorized sh
